Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain can… Read more
Northwest Biotherapeutics Inc (NWBO) - Net Assets
Latest net assets as of September 2025: $-108.65 Million USD
Based on the latest financial reports, Northwest Biotherapeutics Inc (NWBO) has net assets worth $-108.65 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.61 Million) and total liabilities ($139.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-108.65 Million |
| % of Total Assets | -354.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14092.86 |
Northwest Biotherapeutics Inc - Net Assets Trend (2000–2024)
This chart illustrates how Northwest Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Northwest Biotherapeutics Inc (2000–2024)
The table below shows the annual net assets of Northwest Biotherapeutics Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-94.49 Million | -43.66% |
| 2023-12-31 | $-65.77 Million | +48.66% |
| 2022-12-31 | $-128.10 Million | -3.32% |
| 2021-12-31 | $-123.99 Million | +65.84% |
| 2020-12-31 | $-362.95 Million | -733.08% |
| 2019-12-31 | $-43.57 Million | +7.62% |
| 2018-12-31 | $-47.16 Million | +0.28% |
| 2017-12-31 | $-47.29 Million | -78.47% |
| 2016-12-31 | $-26.50 Million | -466.70% |
| 2015-12-31 | $-4.68 Million | +86.65% |
| 2014-12-31 | $-35.03 Million | -3770.39% |
| 2013-12-31 | $-905.00K | +82.10% |
| 2012-12-31 | $-5.06 Million | +90.31% |
| 2011-12-31 | $-52.17 Million | -88.46% |
| 2010-12-31 | $-27.68 Million | -33.83% |
| 2009-12-31 | $-20.69 Million | -68.18% |
| 2008-12-31 | $-12.30 Million | -311.81% |
| 2007-12-31 | $5.81 Million | +197.61% |
| 2006-12-31 | $-5.95 Million | +47.90% |
| 2005-12-31 | $-11.42 Million | -118.86% |
| 2004-12-31 | $-5.22 Million | -32706.25% |
| 2003-12-31 | $16.00K | -99.67% |
| 2002-12-31 | $4.88 Million | -71.21% |
| 2001-12-31 | $16.93 Million | +1173.19% |
| 2000-12-31 | $-1.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Northwest Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 144349900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $1.35 Billion | % |
| Total Equity | $-94.49 Million | 100.00% |
Northwest Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Northwest Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Diversified Royalty Corp
PINK:BEVFF
|
$316.11 Million |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
$316.28 Million |
|
Sparebank 1 Ringerike Hadeland
OL:RING
|
$316.55 Million |
|
Gemtek Technology Co Ltd
TW:4906
|
$316.55 Million |
|
Hidili Industry International Development Limited
PINK:HIIDQ
|
$316.04 Million |
|
Cerence Inc
NASDAQ:CRNC
|
$315.95 Million |
|
Hypothekarbank Lenzburg AG
SW:HBLN
|
$315.92 Million |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
$315.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Northwest Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -65,773,000 to -94,487,000, a change of -28,714,000.
- Net loss of 83,778,000 reduced equity.
- New share issuances of 22,418,000 increased equity.
- Other factors increased equity by 32,646,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-83.78 Million | -88.67% |
| Share Issuances | $22.42 Million | +23.73% |
| Other Changes | $32.65 Million | +34.55% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Northwest Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.21 | $0.21 | x |
| 2014-12-31 | $-0.51 | $0.21 | x |
| 2015-12-31 | $-0.05 | $0.21 | x |
| 2016-12-31 | $-0.17 | $0.21 | x |
| 2017-12-31 | $-0.20 | $0.21 | x |
| 2018-12-31 | $-0.09 | $0.21 | x |
| 2019-12-31 | $-0.07 | $0.21 | x |
| 2020-12-31 | $-0.44 | $0.21 | x |
| 2021-12-31 | $-0.13 | $0.21 | x |
| 2022-12-31 | $-0.12 | $0.21 | x |
| 2023-12-31 | $-0.06 | $0.21 | x |
| 2024-12-31 | $-0.07 | $0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Northwest Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6062.08%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -328300.00% | 0.05x | 0.00x | $-27.61 Million |
| 2013 | 0.00% | -8132.14% | 0.04x | 0.00x | $-64.81 Million |
| 2014 | 0.00% | -9328.34% | 0.02x | 0.00x | $-132.13 Million |
| 2015 | 0.00% | -6598.10% | 0.02x | 0.00x | $-114.27 Million |
| 2016 | 0.00% | -12875.44% | 0.01x | 0.00x | $-77.56 Million |
| 2017 | 0.00% | -21768.75% | 0.01x | 0.00x | $-66.41 Million |
| 2018 | 0.00% | -8687.86% | 0.02x | 0.00x | $-31.08 Million |
| 2019 | 0.00% | -842.16% | 0.26x | 0.00x | $-15.94 Million |
| 2020 | 0.00% | -41039.58% | 0.04x | 0.00x | $-493.53 Million |
| 2021 | 0.00% | 17823.48% | 0.03x | 0.00x | $191.53 Million |
| 2022 | 0.00% | -6240.76% | 0.05x | 0.00x | $-92.22 Million |
| 2023 | 0.00% | -3240.11% | 0.07x | 0.00x | $-56.02 Million |
| 2024 | 0.00% | -6062.08% | 0.05x | 0.00x | $-74.33 Million |
Industry Comparison
This section compares Northwest Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Northwest Biotherapeutics Inc (NWBO) | $-108.65 Million | 0.00% | N/A | $316.05 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |